Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Leading industry innovators to explore latest developments in 3D Cell Culture

SMi Group
Posted on: 07 Oct 16
Leading industry innovators to explore latest developments in 3D Cell Culture

AstraZeneca, GSK, Lonza, MHRA, Novartis, and Sanofi join speaker lineup at SMi’s inaugural event on 3D Cell Culture in February. 

Following the success of the sell-out Cell Based Assay series, SMi Group has launched its inaugural conference on 3D Cell Culture which takes place on the 22nd and 23rd of February 2017 in London. The agenda, as well as registration, is now live on

With a focus on clinical successes and emerging technologies, the conference will showcase how 3D Cell Culture has revolutionized drug discovery and toxicity screening, as well as how it is emerging as an invaluable tool in stem cell research and regenerative medicine.

The event will also highlight exciting opportunities and latest innovations, spheroid and organoid techniques, as well as key developments in 3D and 4D bio-printing, microfluidics, CRISPR and the ongoing debate of 2D vs 3D cell culture.

In line with this, GE Healthcare Life Sciences will host an exclusive half-day pre-conference workshop on bio-printing on 21st February 2017.

Highlights of the event will include:

  • a comparison of the benefits and potential of 3D Cell Culture over 2D Cell Culture with Stefan Przyborski, Professor of Cell Technology, Durham University
  • Sanofi Aventis will be giving a technology update and comparisons of the latest technology available to 3D Cell Culture;
  • insights into high throughtput screening, and the use of CRISPR in 3D cultures from Novartis;
  • GlaxoSmithKline's take on the use of 3D Cell Culture in toxicity investigations;
  • a presentation by MHRA to discuss the European regulatory considerations for use of cells in drug manufacturing;
  • the Hubrecht Organoid Technology Foundation explains how to harness organoid technology for personalised models of drug discovery; and
  • successful case studies on drug discovery and target validation with AstraZeneca

A detailed two-day agenda is available to download on the event website.

For more details about the conference and registration information, visit

3D Cell Culture
22 & 23 February 2017
Copthorne Tara Hotel, London, UK

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at For delegate queries please contact Matthew Apps at For media queries please contact Honey de Gracia at

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

For more information:

Editor's Details

SMi Group

Last updated on: 07/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.